Caribou Biosciences (CRBU) Earnings Date & Reports

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

CRBU is expected to report earnings to rise 16.23% to -45 cents per share on May 13

Caribou Biosciences CRBU Stock Earnings Reports

Q1'25

Est.

$-0.45

Q4'24

Beat

by $0.03

Q3'24

Beat

by $0.07

Q2'24

Beat

by $0.04

Q1'24

Missed

by $0.06

The last earnings report on March 10 showed earnings per share of -38 cents, beating the estimate of -41 cents. With 1.43M shares outstanding, the current market capitalization sits at 71.99M.

View a ticker or compare two or three

Compare

CRBU